Dyadic Advances Its Partnership with IIBR

Dyadic Strengthens Collaboration with Israel Institute for Biological Research (IIBR) to Address Bio-Threats and Emerging Disease Solutions

Overview

Dyadic International, Inc. (NASDAQ: DYAI), a prominent biotechnology firm specializing in advanced microbial platforms for protein development and bioproduction, has announced a significant advancement in its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm, Life Science Research Israel (LSRI). The collaboration aims to target emerging diseases by leveraging Dyadic's expertise in microbial platforms for protein bioproduction and IIBR's capabilities in antibodies and antigens discovery.

Objectives of Partnership

• This partnership seeks to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. 

• By combining Dyadic's flexible scale protein bioproduction technologies with IIBR's antibodies and antigens discovery capabilities, the goal is to create effective treatments and vaccines to combat global health challenges. 

• The intention is to eventually commercialize these solutions through collaborative out-licensing initiatives, although the current framework is non-binding and subject to the negotiation of a binding agreement.

Dyadic on Partnership

• Dyadic, expressed enthusiasm about advancing the collaboration with IIBR. 

• The joint effort will involve enhancing Dyadic's C1 cell lines using proprietary gene sequences from IIBR to improve the biomanufacturing of recombinant vaccines and neutralizing agents, including targeted antigens and monoclonal antibodies. 

• The focus is on addressing emerging diseases through global commercial out-licensing initiatives to enhance access and affordability of vaccines and antibodies.

Collab to Deal with Biothreats

• Baruch Shahar, General Manager of LSRI, highlighted the longstanding collaboration between LSRI and Dyadic, which began in January 2018 and expanded during the pandemic. Mr. Shahar emphasized their satisfaction with the ongoing work using Dyadic's C1 technology to co-develop vaccines and treatments for biological outbreaks, including pandemics and other threats. 

• The collaboration aims to expedite the development of safe, protective, and cost-effective vaccines and treatments against various biothreat agents, including toxins, viruses, and bacteria.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!